Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Study of Naxitamab Added to Induction Therapy for Subjects With Newly Diagnosed High-Risk Neuroblastoma

NCT05489887 is registered in ClinicalTrials.gov with Giselle Sholler as lead sponsor.

NCT NCT05489887
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05489887 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Study of Naxitamab Added to Induction Therapy for Subjects With Newly Diagnosed High-Risk Neuroblastoma
Lead sponsor
Giselle Sholler
Phase
Phase 2
Overall status
Recruiting
Start date
September 14, 2022
Completion date
September 30, 2036
Enrollment
93 (estimated)
Sites
26

Conditions

As the registry lists them; a condition with its own page is linked.

neuroblastoma